These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 36204568)

  • 1. NLRP3 inflammasome: The rising star in cardiovascular diseases.
    Zheng Y; Xu L; Dong N; Li F
    Front Cardiovasc Med; 2022; 9():927061. PubMed ID: 36204568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NLRP3 Inflammasome as a Common Denominator of Atherosclerosis and Abdominal Aortic Aneurysm.
    Takahashi M
    Circ J; 2021 Nov; 85(12):2129-2136. PubMed ID: 33883388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NLRP3: A Novel Mediator in Cardiovascular Disease.
    Zhou W; Chen C; Chen Z; Liu L; Jiang J; Wu Z; Zhao M; Chen Y
    J Immunol Res; 2018; 2018():5702103. PubMed ID: 29850631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of NLRP3 Inflammasome in Diabetic Cardiomyopathy and Its Therapeutic Implications.
    Ding K; Song C; Hu H; Yin K; Huang H; Tang H
    Oxid Med Cell Longev; 2022; 2022():3790721. PubMed ID: 36111168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases.
    Wang Y; Liu X; Shi H; Yu Y; Yu Y; Li M; Chen R
    Clin Transl Med; 2020 Jan; 10(1):91-106. PubMed ID: 32508013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk of NLRP3 inflammasome and noncoding RNAs in cardiomyopathies.
    Jafari N; Shahabi Rabori V; Zolfi Gol A; Saberiyan M
    Cell Biochem Funct; 2023 Dec; 41(8):1060-1075. PubMed ID: 37916887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications.
    Pellegrini C; Martelli A; Antonioli L; Fornai M; Blandizzi C; Calderone V
    Med Res Rev; 2021 Jul; 41(4):1890-1926. PubMed ID: 33460162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NLRP3 inflammasome as a key driver of vascular disease.
    Takahashi M
    Cardiovasc Res; 2022 Jan; 118(2):372-385. PubMed ID: 33483732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases.
    An N; Gao Y; Si Z; Zhang H; Wang L; Tian C; Yuan M; Yang X; Li X; Shang H; Xiong X; Xing Y
    Front Immunol; 2019; 10():1592. PubMed ID: 31354731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation and Function of the Nucleotide Binding Domain Leucine-Rich Repeat-Containing Receptor, Pyrin Domain-Containing-3 Inflammasome in Lung Disease.
    Lee S; Suh GY; Ryter SW; Choi AM
    Am J Respir Cell Mol Biol; 2016 Feb; 54(2):151-60. PubMed ID: 26418144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.
    Wang Z; Hu W; Lu C; Ma Z; Jiang S; Gu C; Acuña-Castroviejo D; Yang Y
    Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2765-2779. PubMed ID: 30571177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 Inflammasome Activation: A Therapeutic Target for Cerebral Ischemia-Reperfusion Injury.
    Wang L; Ren W; Wu Q; Liu T; Wei Y; Ding J; Zhou C; Xu H; Yang S
    Front Mol Neurosci; 2022; 15():847440. PubMed ID: 35600078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRP3 inflammasome and pyroptosis in cardiovascular diseases and exercise intervention.
    Ding P; Song Y; Yang Y; Zeng C
    Front Pharmacol; 2024; 15():1368835. PubMed ID: 38681198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Mechanisms and Effects of Chinese Medicines in Treatment of Diabetic Atherosclerosis by Modulating NLRP3 Inflammasome: A Narrative Review.
    Yuan JY; Fu Y; Feng ZH; Sang F; Shao MY; Li LL
    Chin J Integr Med; 2022 Aug; 28(8):753-761. PubMed ID: 35507299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease.
    Wang S; Yuan YH; Chen NH; Wang HB
    Int Immunopharmacol; 2019 Feb; 67():458-464. PubMed ID: 30594776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy.
    Zeng C; Duan F; Hu J; Luo B; Huang B; Lou X; Sun X; Li H; Zhang X; Yin S; Tan H
    Redox Biol; 2020 Jul; 34():101523. PubMed ID: 32273259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy.
    Zhang L; Ai C; Bai M; Niu J; Zhang Z
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NLRP3 inflammasome in endothelial dysfunction.
    Bai B; Yang Y; Wang Q; Li M; Tian C; Liu Y; Aung LHH; Li PF; Yu T; Chu XM
    Cell Death Dis; 2020 Sep; 11(9):776. PubMed ID: 32948742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in research on cardiomyocyte pyroptosis mediated by NLRP3 inflammasome and traditional Chinese medicine intervention].
    Ge ZS; Xu ZM; Li P
    Zhongguo Zhong Yao Za Zhi; 2021 Oct; 46(20):5210-5217. PubMed ID: 34738421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Specific Roles of NLRP3 Inflammasome in Myocardial Infarction.
    Takahashi M
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):188-193. PubMed ID: 31356542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.